UVA scientists find potential explanation for mysterious cell death in Alzheimer’s, Parkinson’s

Genetic variation in individual neurons may have big effect as we age

Scientists at the University of Virginia School of Medicine have identified a potential explanation for the mysterious death of specific brain cells seen in Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

Genetic variations inside individual neurons may explain the mysterious cell death seen in Alzheimer's, Parkinson's and other neurodegenerative diseases, UVA researcher Michael McConnell, PhD, has determined.

The new research suggests that the cells may die because of naturally occurring gene variation in brain cells that were, until recently, assumed to be genetically identical. This variation – called “somatic mosaicism” – could explain why neurons in the temporal lobe are the first to die in Alzheimer’s, for example, and why dopaminergic neurons are the first to die in Parkinson’s.

This has been a big open question in neuroscience, particularly in various neurodegenerative diseases. What is this selective vulnerability? What underlies it? And so now, with our work, the hypotheses moving forward are that it could be that different regions of the brain actually have a different garden of these [variations] in young individuals and that sets up different regions for decline later in life.”

Neuroscientist Michael McConnell, PhD, UVA’s Center for Brain Immunology and Glia (BIG)

A most unexpected outcome

The finding emerged unexpectedly from McConnell’s investigations into schizophrenia. It was in that context that he and his collaborators first discovered the unexpected variation in the genetic makeup of individual brain cells. That discovery may help explain not just schizophrenia but depression, bipolar disorder, autism and other conditions.

Continuing his investigations, McConnell expected that this mosaicism would increase with age – that mutations would accumulate over time. What he and his collaborators at Johns Hopkins found is exactly the opposite: Younger people had the most mosaicism and older people had the least.

We wound up building an atlas that contained neurons from 15 individuals. None of these individuals had disease. They ranged in age from less than a year to 94 years, and it showed a perfect correlation – a perfect anti-correlation – with age.”

Michael McConnell, PhD, UVA’s Department of Biochemistry and Molecular Genetics and UVA’s Department of Neuroscience

Based on the finding, McConnell believes that the neurons with significant genetic variation, known as CNV neurons, may be the most vulnerable to dying. And that could explain the idiosyncratic death of specific neurons in different neurodegenerative diseases. People with the most CNV neurons in the temporal lobe, for example, might be likely to develop Alzheimer’s.

More work needs to be done to fully understand what’s occurring, McConnell said. So far, he has only looked at neurons in the frontal cortex of the brain, and his studies are limited by the fact that neurons can be examined only after death, so it can be hard to make direct comparisons. But he is excited to expand the scope of his research.

“Because I'm collaborating with the Lieber Institute and they have this fantastic brain bank, now I can look at individuals’ frontal cortex [for the schizophrenia research] and I can look at the temporal lobe in those same individuals,” McConnell said. “So now I can really start to map things out more carefully, building an atlas of different brain regions from many individuals.”

That research could greatly advance our understanding of both neurodegenerative diseases and the cognitive decline that besets us with age, potentially leading to new treatments.

“What's really interesting about mosaicism is that it is fundamentally tweaking our assumptions about what nature is, because we've kind of always assumed that every cell in any given individual had the same genome, the same DNA in every cell,” McConnell said. “And now we're showing that it’s different and what that might mean.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Next-generation cell-penetrating antibodies could transform cancer treatment